Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)

Recruiting N/A Interventional Study
Uveal Melanoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Health Services Research
Participants needed
700 (estimated)
Sponsor
Institut Curie · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Patient aged of 18 years or more. 2. Patient with uveal melanoma with high metastatic relapse risk defined as : * T2b/c/d ou ≥ T3, * or chromosom 3 or chromosom 8 abnormality by CGH array. 3. Completion of treatment of the primary tumor ≤ 2 months. 4. Patient able to c…
Contacts

Sophie Piperno-Neumann, MD

01 44 32 46 72

sophie.piperno-neumann@curie.fr

CONTACT

Marie-Emmanuelle Legrier, PhD

01 56 24 56 49

drci.promotion@curie.fr

CONTACT